" class="no-js "lang="en-US"> Hung-Kai Chen - Medtech Alert
Thursday, March 30, 2023
Hung-Kai Chen

Hung-Kai Chen

About Hung-Kai Chen

Broad research and development experience from early drug discovery to late-stage clinical development for both small molecules and biologics.

Related Story

Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo Clinical-Stage Assets

August 23 2021

Elixiron Immunotherapeutics, Inc., a privately held company developing therapeutics for cancer, neurological diseases and inflammatory […]